Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China.
Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Front Immunol. 2024 Jan 8;14:1334408. doi: 10.3389/fimmu.2023.1334408. eCollection 2023.
A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.
Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.
TLS+, TLS, TLS+GC+ and CD8 within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.
We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.
三级淋巴结构(TLS)是指免疫细胞的有序浸润,与预后良好和对免疫治疗的反应改善有关。然而,促进 TLS 形成的方法有限,并且在临床环境中难以实施。在这项研究中,我们旨在通过将低剂量放疗(LDRT)与免疫疗法相结合,促进肺腺癌(LUAD)中 TLS 的形成和成熟。
检查了 198 例接受手术的患者的组织切片。评估了患者生存的危险因素,并分析了 TLS 与五年生存率的关系。使用 Kras-LSL-G12D 自发性肺癌小鼠模型筛选促进 TLS 形成的最佳照射剂量(0/1/2 Gy 全肺照射)。LDRT 联合抗 PD-1 用于促进 TLS 的形成和成熟。
TLS+、TLS、TLS+GC+和 TLS+内的 CD8 与预后良好相关。LDRT 增加了 Kras-LSL-G12D 肺癌小鼠模型中早期 TLS 的形成。此外,LDRT 联合抗 PD-1 治疗可显著提高小鼠 LUAD 中 TLS 的成熟度,从而产生更强的抗肿瘤作用。这种抗肿瘤作用与 TLS 内 CD8+T 细胞的数量密切相关。
我们首次成功应用 LDRT 联合 PD-1 抑制剂治疗,增加了肺癌中 TLS 的数量和成熟度。这种方法取得了有前景的抗肿瘤效果。